Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Bethanie Miller

Nurse Practitioner, Family Maplewood, MN Nurse Practitioner

NPI 1811650518 CMS profile 11275037

1725 Legacy Pkwy E Ste 100, Maplewood, MN 55109

Open in the dashboard

General payments

$7,208

99 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bethanie Miller of Maplewood, MN is reported in the CMS Open Payments database as having received $7,208 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $304 6
2024 General $2,949 29
2023 General $2,585 52
2022 General $1,370 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bethanie Miller
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Bethanie Miller were reported at $304. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Bethanie Miller Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $1,370 $141 $44–$430 $149
2023 $2,585 $154 $49–$476 $160
2024 $2,949 $165 $51–$504 $164
2025 $304 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $3,133 38 payments
  2. Medtronic, Inc. $2,429 34 payments
  3. SI-BONE, Inc. $1,004 11 payments
  4. Nevro Corp. $369 7 payments
  5. SPR Therapeutics, Inc $107 2 payments
  6. Vertos Medical, Inc. $70 2 payments
  7. Relievant Medsystems, Inc. $44 2 payments
  8. Sanofi-Aventis U.S. LLC $19 1 payment
  9. Collegium Pharmaceutical, Inc. $17 1 payment
  10. Teva Pharmaceuticals USA, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,936 81 payments
  2. Travel and Lodging $3,191 15 payments
  3. Education $81 3 payments
Products named General payments · program years 2022–2025
  1. SYNCHROMEDII $1,754 23 payments
  2. Intracept $1,616 10 payments
  3. Spectra WaveWriter $884 3 payments
  4. IFUSE IMPLANT SYSTEM $796 4 payments
  5. INTELLIS ADAPTIVESTIM $675 11 payments
  6. WaveWriter Alpha Prime 16 $307 7 payments
  7. Senza $223 5 payments
  8. Omnia $146 2 payments
  9. Superion Indirect Decompression System $140 12 payments
  10. SPRINT PNS System $107 2 payments
  11. Other $322 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,198

Median for Nurse Practitioner: 389

Drug cost

$110,491

Median for Nurse Practitioner: $21,885

Branded share of claims

32.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 17 $20,846
Oxycontin Oxycodone Hcl Brand 30 $16,941
Buprenorphine Generic 55 $14,047
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 342 $10,624
Oxycodone Hcl Generic 289 $6,340
Movantik Naloxegol Oxalate Brand 13 $5,126
Fentanyl Generic 49 $4,574
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 181 $4,274
Gabapentin Generic 170 $3,838
Duloxetine Hcl Generic 88 $3,590

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$58,823

Medicare's payments for the services billed

Medicare patients

103

Average age 71

Services billed

715

74 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 66%
Depression 45%
Chronic kidney disease 29%
Ischemic heart disease 26%
Diabetes 21%
Osteoporosis 19%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record